News: Portfolio 2006

OraQuick ADVANCE(R) to Be Centerpiece of Expanded HIV Testing in Philadelphia

(continued)

 

"OraSure is thrilled to be working with the City of Philadelphia and the Commonwealth of Pennsylvania on this HIV testing campaign. This campaign illustrates the commitment of individuals like Senator Hughes and Secretary Johnson who recognize the importance of knowing your HIV status in order to help stem the spread of the disease," said OraSure President and Chief Executive Officer, Douglas A. Michels speaking at the press conference. "Our OraQuick ADVANCE(R) HIV 1/2 test is ideally suited for broad-scale testing initiatives because of its simplicity, its high accuracy, and very importantly, its oral fluid capability. We are extremely pleased to be a partner in this effort."

In June 2006, Washington D.C. announced a broad-scale campaign to test residents in the district for HIV-1 and HIV-2 using OraQuick ADVANCE(R). Philadelphia's campaign represents the second city-based HIV testing initiative launched this year, and is expected to serve as an additional model for large cities across the country in support of the Centers for Disease Control and Prevention's recently issued recommendations for routine HIV testing in healthcare settings.

 

The OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, manufactured and sold by OraSure Technologies, is the first and only U.S. Food and Drug Administration ("FDA") approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood and plasma specimens.

 

 

Page: 1 2 3 4 5